Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.54 |
| ▸ | AXL | P30530 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 6/20 | 0.43 |
| ▸ | JAK3 | P52333 | 5/20 | 0.43 |
| ▸ | JAK1 | P23458 | 4/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.38 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.38 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29486783 | 1.00 | PRKCI (0.54) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL17495401 | 0.81 | PRKCI (0.46) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL30213789 | 0.81 | PRKCI (0.46) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL22941677 | 0.81 | JAK2 (0.43) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL24678876 | 0.79 | AXL (0.43) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL30084195 | 0.79 | AXL (0.43) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL14795009 | 0.77 | JAK2 (0.43) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL15422239 | 0.77 | JAK2 (0.41) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL17963822 | 0.77 | JAK2 (0.54) | PRKCIAXLJAK2JAK3JAK1 | |
| SCHEMBL9989739 | 0.77 | GSK3B (0.49) | JAK2JAK3JAK1TYK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4620469-A2 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4582425-A1 | PRODRUG OF JAK KINASE INHIBITOR | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd (CN) | 2025-07-09 | — | — | EP | disclosed |
| EP-4175719-B1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-8426411-B2 | Tricyclic compounds | ABBOTT LABORATORIES (US) | 2013-04-23 | — | — | US | disclosed |
| US-20130072470-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072470-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2506716-A1 | NOVEL TRICYCLIC COMPOUNDS | Abbott Laboratories (US) | 2012-10-10 | — | — | EP | disclosed |
| CN-102711476-A | Novel tricyclic compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110311474-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068881-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | PRKCI 135/4885AXL 283/4885JAK2 1/4885 |
| US-20260125379-A1 | PRODRUG OF JAK KINASE INHIBITOR | JAK1, JAK2, JAK3 | PRKCI 286/4885AXL 103/4885JAK2 2/4885 |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | PRKCI 135/4885AXL 283/4885JAK2 1/4885 |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | PRKCI 135/4885AXL 283/4885JAK2 1/4885 |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | PRKCI 135/4885AXL 283/4885JAK2 1/4885 |
| US-20110311474-A1 | Novel Tricyclic Compounds | CYP11B2, CYP11B1, ABCB1 | PRKCI 3511/4885AXL 3763/4885JAK2 356/4885 |
| US-20130072470-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | PRKCI 3389/4885AXL 4096/4885JAK2 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.